Metformin-Induced Vasorelaxation via Endothelium-Dependent Hyperpolarization in Murine Colitis

Study Background and Research Question

Metformin is widely recognized as a first-line therapy for type 2 diabetes mellitus (T2DM), with established roles in glycemic control and emerging evidence for cardiovascular and anti-inflammatory benefits. Recent clinical and preclinical studies suggest metformin exerts protective effects beyond its metabolic actions, including attenuation of tumor growth and reduction of ischemic cardiovascular events. Specifically, its ability to modulate vascular function has garnered attention, but the mechanisms underlying vasorelaxation in resistance vessels—particularly under pathological conditions such as ulcerative colitis (UC)—have not been fully elucidated. The present study (Zhang et al., 2025) addresses a key gap: How does metformin induce vasorelaxation in intestinal resistance arteries during health and colitis, and which cellular pathways are involved?

Key Innovation from the Reference Study

The central innovation of this research is the identification of endothelium-dependent hyperpolarization (EDH) as the predominant pathway mediating metformin-induced vasorelaxation in both healthy and colitic mesenteric arterioles. While nitric oxide (NO) and prostacyclin (PGI₂) are classical endothelium-derived relaxing factors, EDH is increasingly recognized as critical for modulating the tone of resistance arteries. This study not only demonstrates that metformin acts via EDH, but also reveals that this mechanism remains robust under UC conditions, in contrast to the severely impaired acetylcholine (ACh)-induced EDH responses. These findings suggest a novel therapeutic window for repurposing metformin to restore vascular homeostasis in inflammatory diseases of the gut.

Methods and Experimental Design Insights

The research employed a comprehensive and rigorous methodological approach to dissect the vasorelaxant actions of metformin:

• Vascular reactivity was assessed using Mulvany-style wire myography in both human submucosal arterioles and mouse mesenteric arteries, allowing quantification of vessel tone in response to pharmacological agents.
• Comparative analyses were performed using wild-type C57BL/6 mice and TRPV4 knockout (KO) mice, clarifying the contributions of transient receptor potential vanilloid 4 channels to endothelial signaling.
• Mouse models of ulcerative colitis were established using dextran sodium sulfate (DSS), enabling investigation of metformin’s actions under inflammatory conditions.
• Mechanistic studies included Ca²⁺ imaging and patch-clamp electrophysiology in human umbilical vein endothelial cells (HUVECs), focusing on intracellular signaling cascades.

This multi-tiered design allowed for cross-validation of findings across species, disease states, and cellular systems, increasing the robustness and translational relevance of the conclusions.

Core Findings and Why They Matter

The study found that metformin produces potent vasorelaxation in mesenteric arterioles primarily through EDH, both in healthy and colitic tissue. Mechanistically, metformin triggers endoplasmic reticulum (ER) Ca²⁺ release via the PLC/IP₃/IP₃R pathway and enhances Ca²⁺ influx through store-operated Ca²⁺ entry (SOCE) and TRPV4 channels in endothelial cells. This cascade leads to membrane hyperpolarization and vascular smooth muscle relaxation.

Crucially, while acetylcholine-induced EDH responses were almost entirely lost in colitic vessels, metformin-induced EDH-mediated vasorelaxation persisted, effectively compensating for the impaired endogenous pathway. This preservation of EDH function was associated with improved mucosal hemoperfusion and amelioration of colitis pathology, highlighting metformin's potential to rescue vascular dysfunction during inflammation (Zhang et al., 2025).

Protocol Parameters

• DSS-Induced Colitis Model: C57BL/6 mice receive dextran sodium sulfate in drinking water to induce UC-like pathology before vascular studies.
• Wire Myograph Analysis: Isolate mesenteric or submucosal arterioles (human or mouse), mount on myograph, and precontract with phenylephrine before cumulative addition of metformin or acetylcholine to assess relaxation.
• Endothelial Signaling Dissection: Use pharmacological inhibitors (e.g., indomethacin for prostacyclin, L-NAME for nitric oxide synthase) to isolate EDH contributions.
• Calcium Imaging/Patch-Clamp: In HUVECs, apply metformin and monitor ER Ca²⁺ release, SOCE, and membrane currents to validate endothelial signaling pathways.
• TRPV4 KO Controls: Compare responses in wild-type versus TRPV4-deficient mice to determine channel-specific roles in vasorelaxation.

Comparison with Existing Internal Articles

The present findings align with and extend prior internal reports, notably the article "Metformin-Induced Vasorelaxation via EDH in Murine Colitis Models", which first highlighted EDH as a compensatory pathway when acetylcholine responses are blunted in colitis. The new evidence provides deeper mechanistic insight, implicating specific intracellular Ca²⁺ signaling routes and TRPV4 channels, and demonstrating that metformin’s effect is not merely preserved but can actively rescue impaired vasorelaxation. Relatedly, "Metformin-Induced EDH in Colitis: Mechanisms and Implications" supports the view that EDH is central to microvascular adaptation in inflammatory states, reinforcing the translational significance of these mechanisms for cardiovascular and inflammatory research.

In the context of ion homeostasis and cardiovascular research, the use of selective Na⁺/K⁺-ATPase inhibitors such as ouabain has been instrumental in dissecting the interplay between endothelial signaling and vascular smooth muscle tone (see "Ouabain as a Precision Tool for Ion Homeostasis and Cardi..."). While the current study centers on metformin and EDH, such tools facilitate complementary analyses of ion gradient-dependent signaling in vascular physiology.

Limitations and Transferability

Despite the thorough experimental design, several limitations warrant consideration. The primary data derive from acute ex vivo studies and murine models, which, while highly informative, may not fully recapitulate the complexity of human UC or systemic inflammation. The focus on mesenteric arterioles provides valuable insight into intestinal microcirculation but may not directly translate to other vascular beds. Additionally, the molecular specificity of metformin’s actions—whether unique to this biguanide or shared with other agents—remains to be clarified. Further studies are needed to assess the persistence of these effects during chronic inflammation and in clinical settings.

Research Support Resources

For researchers investigating vascular ion transport, endothelial signaling, or cardiovascular models, the use of validated chemical probes is essential. Ouabain (SKU B2270) from APExBIO is a potent, selective Na⁺/K⁺-ATPase inhibitor widely used to perturb sodium-potassium pump activity in vascular and cellular experiments. As detailed in recent workflow guides, ouabain enables precise dissection of ion gradient-dependent mechanisms and is especially valuable in Na⁺/K⁺-ATPase inhibition assays, studies of ion transport, and heart failure animal models. For protocol improvements or cross-validation in endothelial and smooth muscle research, consider integrating ouabain into your experimental design as supported by the internal workflow resources. Please consult the product information for storage and handling recommendations.